Financials
| Full Year Results for the 12mths to 30 June 2025 | Oct. 14, 2025 |
| Trading Update | Jul. 31, 2025 |
| Interim Results | Mar. 11, 2025 |
| Half Year Trading Update | Jan. 28, 2025 |
| Commercial Trading Update | Nov. 06, 2024 |
| Posting of Annual Report and Notice of AGM | Nov. 05, 2024 |
| Full Year Results for the 12mths to 30 June 2024 | Oct. 22, 2024 |
Proxies
| Results of 2025 Annual General Meeting | Nov. 27, 2025 |
| AGM Statement | Nov. 27, 2025 |
| Results of 2024 Annual General Meeting | Nov. 29, 2024 |
| AGM Statement | Nov. 29, 2024 |
| Results of 2023 Annual General Meeting | Dec. 15, 2023 |
| AGM Statement | Dec. 15, 2023 |
| Posting of Annual Report and Notice of AGM | Nov. 20, 2023 |
Ownership Update
| Notification of dealings by a director/PDMR | Sep. 09, 2025 |
| Holding(s) in Company | Aug. 07, 2025 |
| Holding(s) in Company | Aug. 05, 2025 |
| Holding(s) in Company | Jul. 28, 2025 |
| Issue of Equity in lieu of Non-Exec Director Fees | Jul. 18, 2025 |
| Holding(s) in Company | Jul. 09, 2025 |
| TR-1: Standard form notification of major holdings | Feb. 27, 2025 |
Announcements
| Strong contract wins build commercial momentum | Nov. 14, 2025 |
| New contract with top 10 pharma | Oct. 13, 2025 |
| Notice of Results, Analyst & Investor Presentation | Oct. 10, 2025 |
| New contract with Metir plc | Sep. 11, 2025 |
| Therapeutic development agreement with Invizius | Sep. 02, 2025 |
| Block Listing Interim Review | Aug. 28, 2025 |
| Update on licensing and development progress | Aug. 22, 2025 |